Vanda Pharmaceuticals’ (VNDA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a $18.00 price target on the biopharmaceutical company’s stock.

Separately, StockNews.com assumed coverage on shares of Vanda Pharmaceuticals in a research note on Tuesday. They issued a “hold” rating on the stock.

Vanda Pharmaceuticals Trading Down 0.2 %

NASDAQ VNDA opened at $4.44 on Tuesday. Vanda Pharmaceuticals has a 1-year low of $3.46 and a 1-year high of $6.75. The company has a market capitalization of $258.90 million, a PE ratio of -15.86 and a beta of 0.77. The firm’s fifty day simple moving average is $4.72 and its 200-day simple moving average is $4.98.

Insider Transactions at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the transaction, the director now directly owns 44,857 shares of the company’s stock, valued at $231,910.69. This represents a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 8.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several hedge funds have recently bought and sold shares of VNDA. Dimensional Fund Advisors LP increased its position in Vanda Pharmaceuticals by 17.0% during the second quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company’s stock worth $11,379,000 after buying an additional 292,172 shares during the last quarter. XTX Topco Ltd acquired a new position in Vanda Pharmaceuticals during the second quarter worth $75,000. AQR Capital Management LLC increased its position in Vanda Pharmaceuticals by 181.7% during the second quarter. AQR Capital Management LLC now owns 75,889 shares of the biopharmaceutical company’s stock worth $429,000 after buying an additional 48,945 shares during the last quarter. Susquehanna Fundamental Investments LLC increased its position in Vanda Pharmaceuticals by 2.1% during the second quarter. Susquehanna Fundamental Investments LLC now owns 287,677 shares of the biopharmaceutical company’s stock worth $1,625,000 after buying an additional 5,994 shares during the last quarter. Finally, Nantahala Capital Management LLC grew its position in shares of Vanda Pharmaceuticals by 57.3% in the second quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company’s stock valued at $9,003,000 after purchasing an additional 580,265 shares during the last quarter. 88.14% of the stock is owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.